Nurix Therapeutics, Inc. NRIX

23.08 (0.57) (2.41%) as of 25 Sep
Market cap
$2.5B
P/E
0.0×

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Nov '25 Nov '24 Nov '23 Nov '22 Nov '21 Nov '20 Nov '19 Nov '18 Nov '17
Net Income
(264.46) (193.57) (143.95) (180.36) (117.19) (43.24) (21.70) (9.43) 0.00
Depreciation & Amortization
8.53 5.14 8.23 11.23 7.79 2.45 2.25 2.63 —
Non Cash Items (Other)
38.05 33.96 34.23 28.14 15.93 4.30 0.51 0.43 —
Accounts Receivable Change
— — — 6.00 (6.00) (11.35) — 12.37 —
Accounts Payable Change
(0.63) 5.21 1.61 0.09 1.59 1.23 0.30 (0.52) —
Change in payables and accrued liability
17.31 11.82 3.12 7.49 6.22 2.28 2.37 0.55 —
Income tax paid
— — — 0.00 3.64 (3.85) 0.00 12.37 —
Change in other assets and liabilities
(48.28) (35.43) 15.38 (32.59) 3.66 36.74 16.87 (37.71) —
Other operating activities
— 0.29 — 0.20 — — — (0.01) 0.00
Operating Cash Flow
(249.46) (172.58) (81.36) (159.81) (84.36) (0.08) 0.60 (31.67) —
Capital expenditures
(14.00) (9.27) (8.40) (12.24) (5.66) (4.55) (1.65) (1.59) —
Long-Term Investments Change (Net)
161.86 (248.44) 76.70 39.44 (102.59) (249.85) 10.15 41.58 —
Investing cash flow
147.85 (257.71) 68.30 27.20 (108.25) (254.40) 8.50 39.99 —
Equity Repurchase (Common, Net)
3.88 296.94 3.22 22.43 153.88 219.11 0.13 0.53 —
Equity Repurchase (Preffered, Net)
— — — — — 119.91 — — —
Other financial activities
234.76 188.73 — 94.76 17.63 4.57 0.40 0.07 —
Financing cash flow
238.64 485.67 3.22 117.19 153.88 339.02 0.13 0.53 —
Change in Cash
137.03 55.37 (9.85) (15.42) (38.73) 84.54 9.23 8.85 —
Beginning Cash
110.90 55.53 65.38 80.79 119.53 34.99 25.76 16.91 —
Ending Cash
247.93 110.90 55.53 65.38 80.79 119.53 34.99 25.76 —
Stock Based Compensation
37.97 33.93 33.67 28.13 15.80 4.30 0.51 0.43 —
Dividends Paid (Common)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash/Marketcap
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Assets Liabilities Change (Total)
(31.60) (18.40) 20.12 (19.02) 9.11 36.41 19.55 (25.31) —
Investments Change (Net)
161.86 (248.44) 76.70 39.44 (102.59) (249.85) 10.15 41.58 —
Issuance/Purchase of Shares
3.88 296.94 3.22 22.43 153.88 339.02 0.13 0.53 —
Other line items
Revenue per Employee
0.26 0.19 0.27 0.13 0.12 0.13 0.30 0.00 —

Fold the line items

In millions of $ except per-share values · columns are period end dates